Business Description
UroGen Pharma Ltd
NAICS : 541714
SIC : 2834
ISIN : IL0011407140
Total Employee Number:
291Description
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.72 | |||||
Equity-to-Asset | -0.49 | |||||
Debt-to-Equity | -1.57 | |||||
Debt-to-EBITDA | -1.62 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -2.56 | |||||
Beneish M-Score | -0.56 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -6.8 | |||||
3-Year EBITDA Growth Rate | 13 | |||||
3-Year EPS without NRI Growth Rate | 12.8 | |||||
3-Year FCF Growth Rate | 4.2 | |||||
3-Year Book Growth Rate | 17.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 69.89 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 63.51 | |||||
9-Day RSI | 66.27 | |||||
14-Day RSI | 67.6 | |||||
3-1 Month Momentum % | 51.46 | |||||
6-1 Month Momentum % | 55.06 | |||||
12-1 Month Momentum % | 115.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.69 | |||||
Quick Ratio | 4.28 | |||||
Cash Ratio | 2.77 | |||||
Days Inventory | 309.51 | |||||
Days Sales Outstanding | 76.63 | |||||
Days Payable | 346.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -27.9 | |||||
Shareholder Yield % | -3.51 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 89.85 | |||||
Operating Margin % | -77.02 | |||||
Net Margin % | -94.83 | |||||
EBITDA Margin % | -85.62 | |||||
FCF Margin % | -118.15 | |||||
OCF Margin % | -117.94 | |||||
ROA % | -60.8 | |||||
ROIC % | -244.13 | |||||
3-Year ROIIC % | -157.95 | |||||
ROC (Joel Greenblatt) % | -589.73 | |||||
ROCE % | -70.87 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 13.69 | |||||
EV-to-EBIT | -15.99 | |||||
EV-to-EBITDA | -16.33 | |||||
EV-to-Revenue | 13.98 | |||||
EV-to-Forward-Revenue | 7.4 | |||||
EV-to-FCF | -11.83 | |||||
Price-to-GF-Value | 1.86 | |||||
Earnings Yield (Greenblatt) % | -6.25 | |||||
FCF Yield % | -8.7 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
UroGen Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 120.802 | ||
| EPS (TTM) (€) | -2.366 | ||
| Beta | 2.2498 | ||
| 3-Year Sharpe Ratio | 0.78 | ||
| 3-Year Sortino Ratio | 2.37 | ||
| Volatility % | 83.65 | ||
| 14-Day RSI | 67.6 | ||
| 14-Day ATR (€) | 0.850685 | ||
| 20-Day SMA (€) | 31.1525 | ||
| 12-1 Month Momentum % | 115.51 | ||
| 52-Week Range (€) | 11.8 - 34.5 | ||
| Shares Outstanding (Mil) | 48.72 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
UroGen Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
UroGen Pharma Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 10:00 | In 115 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 114 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 10:00 | In 24 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 23 days | ||
| General meeting for 2026 | 2026-06-22 10:00 | 28.99 (+0.00%) | ||
| Goldman Sachs 47(th) Annual Global Healthcare Conference | 2026-06-10 08:40 | 23.07 (+0.00%) | ||
| TD Cowen 7(th) Annual Oncology Innovation Summit | 2026-05-26 10:30 | 24.72 (+0.00%) | ||
| HC Wainwright 4(th) Annual BioConnect Investor Conference | 2026-05-19 10:30 | 23.98 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-13 11:15 | 25.99 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 10:00 | 19.48 (+0.00%) |
Show
Entries
UroGen Pharma Ltd Frequently Asked Questions
What is UroGen Pharma Ltd(FRA:UR8)'s stock price today?
The current price of FRA:UR8 is €33.86. The 52 week high of FRA:UR8 is €34.50 and 52 week low is €11.80.
When is next earnings date of UroGen Pharma Ltd(FRA:UR8)?
The next earnings date of UroGen Pharma Ltd(FRA:UR8) is 2026-08-07 Est..
Does UroGen Pharma Ltd(FRA:UR8) pay dividends? If so, how much?
UroGen Pharma Ltd(FRA:UR8) does not pay dividend.
Press Release
Articles on UroGen Pharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers